デフォルト表紙
市場調査レポート
商品コード
1446442

北米の分子診断市場規模、シェア、動向分析レポート:製品別、検査部位別、技術別、用途別、国別、セグメント別予測、2024年~2030年

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology (PCR, ISH, INAAT, Sequencing), By Application, By Country, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.45円
北米の分子診断市場規模、シェア、動向分析レポート:製品別、検査部位別、技術別、用途別、国別、セグメント別予測、2024年~2030年
出版日: 2024年02月01日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の分子診断市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、北米の分子診断市場規模は2024年から2030年にかけてCAGR 4.2%を記録し、2030年には72億3,000万米ドルに達すると予測されています。

技術的に先進的な製品のイントロダクションが北米市場を牽引すると期待されています。分子診断技術の進歩により、多くの疾患の早期発見が可能になり、深刻な経済的・社会的負担の可能性が減少しました。分子診断技術は、PCR、シークエンシング、遺伝子技術を用いて、がん、遺伝性疾患、感染症の早期診断を可能にします。

アルツハイマー病、ターナー症候群、パーキンソン病などの慢性疾患や感染症、遺伝性疾患の有病率の増加は、予測期間中の市場需要を押し上げると予想されます。CDCによると、米国では毎年、がんや糖尿病、慢性腎臓病や呼吸器疾患などの慢性疾患が10人に7人の死亡原因となっています。さらに、A型・B型インフルエンザのような疾病の増加も市場成長を促進すると予測されています。例えば、CDCによると、2021-2022年のインフルエンザシーズンには、900万人がインフルエンザに罹患すると推定されています。

分子診断における臨床研究を実施するための外部資金の増加は、市場の活性化につながると予想されます。資金調達は製品開発プロセスにおいて重要な役割を果たしています。例えば、2023年4月、プロメガ・コーポレーションは、qPCRを用いた学術生命科学研究に2023年に1万5,000米ドルを助成すると発表しました。同様に、2023年6月、Accelerate Diagnostics, Inc.は、Waveプラットフォームと新規迅速検査の開発を加速するために2,400万米ドルを受け取った。このような取り組みにより、中小企業が新規分子診断検査の開発に関与することが期待されます。

主要企業は北米の分子診断において新製品を上市し、より高度で効率的な製品へと変化する購買者のニーズを満たすことで競争力を獲得するために継続的な努力を行っています。例えば、2022年11月、ダナハーの子会社であるセファイドは、トリコモナス症、細菌性膣炎、外陰膣カンジダ症などの様々な疾患を検出するPCR検査であるMultiplex Vaginal Panel(MVP)を発売しました。

さらに、新規治療薬開発のためのメーカーや企業間の戦略的パートナーシップの増加が、市場の成長を促進すると予想されます。例えば、2023年2月、Thermo Fisher Scientific Inc.は、結核やHIVなど様々な感染症用のRT-PCRキットを調達するためにMyLabと提携しました。さらに、2023年1月、QIAGENとHelixは、遺伝子疾患における次世代シーケンサーのコンパニオン診断を強化するために独占的提携を結びました。

北米の分子診断市場レポートハイライト:

  • 製品別では、2023年に北米の分子診断で最大の売上シェアを占めたのは、効率と費用対効果の改善による試薬セグメントでした。
  • 2023年の北米の分子診断市場は、中央検査室部門が、高い市場浸透率と大規模な検査件数により、支配的でした。
  • 技術別では、PCR分野が2023年の北米の分子診断市場で優位を占め、臨床診断において医師や患者の間で最も好まれている技術です。
  • 感染症分野は、北米の感染症罹患率の高さに起因して、2023年の用途分野をリードしました。
  • 米国は、有利な償還政策、大手企業の現地進出、確立されたヘルスケアインフラの存在により、この地域市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 北米の分子診断市場:製品ビジネス分析

  • 北米の分子診断市場:製品の変動分析
  • 機器
  • 試薬
  • その他

第5章 北米の分子診断市場:検査場所のビジネス分析

  • 北米の分子診断市場:検査場所の変動分析
  • ポイント・オブ・ケア
  • セルフテストまたは店頭テスト
  • 中央研究所

第6章 北米の分子診断市場:テクノロジービジネス分析

  • 北米の分子診断市場:技術変動分析
  • PCR
  • In Situハイブリダイゼーション(ISH)
  • 等温核酸増幅技術(INAAT)
  • チップとマイクロアレイ
  • 質量分析
  • シーケンス
  • 転写媒介増幅(TMA)
  • その他

第7章 北米の分子診断市場:用途ビジネス分析

  • 北米の分子診断市場:用途変動分析
  • 腫瘍学
  • 薬理ゲノミクス
  • 感染症
  • 遺伝子検査
  • 神経疾患
  • 循環器疾患
  • 微生物学
  • その他

第8章 北米の分子診断市場:国別ビジネス分析

  • 北米
    • 米国
    • カナダ

第9章 北米の分子診断市場:競合情勢

  • 参入企業
    • BD
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic Inc. (Gen Probe)
    • Illumina, Inc.
    • Johnson & Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche, Ltd.
  • 参入企業の概要
  • 財務実績
  • 製品のベンチマーク
  • 企業の市場シェア分析、2023年
  • 戦略マッピング

第10章 アナリストの視点

図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Molecular Diagnostics Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Molecular Diagnostics Market, By Product, 2018 - 2030 (USD Million)
  • Table 5 North America Molecular Diagnostics Market, By Test Location, 2018 - 2030 (USD Million)
  • Table 6 North America Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 7 North America Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 8 U.S. Molecular Diagnostics market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Molecular Diagnostics market, by Test Location, 2018 - 2030 (USD Million)
  • Table 10 U.S. Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 12 Canada Molecular Diagnostics market, by Product, 2018 - 2030 (USD Million)
  • Table 13 Canada Molecular Diagnostics market, by Test Location, 2018 - 2030 (USD Million)
  • Table 14 Canada Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 North America molecular diagnostics market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT analysis
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 North America molecular diagnostics market: Product movement analysis
  • Fig. 16 Instruments market, 2018 - 2030 (USD Million)
  • Fig. 17 Reagents market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 North America molecular diagnostics market: Test location movement analysis
  • Fig. 20 Point of care market, 2018 - 2030 (USD Million)
  • Fig. 21 Self-test or OTC market, 2018 - 2030 (USD Million)
  • Fig. 22 Central laboratories market, 2018 - 2030 (USD Million)
  • Fig. 23 North America molecular diagnostics market: Technology movement analysis
  • Fig. 24 PCR market, 2018 - 2030 (USD Million)
  • Fig. 25 Nucleic Acid Extraction PCR market, 2018 - 2030 (USD Million)
  • Fig. 26 Others PCR market, 2018 - 2030 (USD Million)
  • Fig. 27 Multiplex PCR market, 2018 - 2030 (USD Million)
  • Fig. 28 Other PCR market, 2018 - 2030 (USD Million)
  • Fig. 29 In Situ Hybridization market, 2018 - 2030 (USD Million)
  • Fig. 30 Isothermal Nucleic Acid Amplification Technology (INAAT) market, 2018 - 2030 (USD Million)
  • Fig. 31 Chips and microarrays market, 2018 - 2030 (USD Million)
  • Fig. 32 Mass spectrometry market, 2018 - 2030 (USD Million)
  • Fig. 33 Sequencing market, 2018 - 2030 (USD Million)
  • Fig. 34 Transcription mediated amplification market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 North America molecular diagnostics market: Application movement analysis
  • Fig. 37 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 38 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 39 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 40 Colorectal cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Cervical cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Kidney cancer market, 2018 - 2030 (USD Million)
  • Fig. 43 Liver cancer market, 2018 - 2030 (USD Million)
  • Fig. 44 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Lung cancer market, 2018 - 2030 (USD Million)
  • Fig. 46 Other cancer market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacogenomics market, 2018 - 2030 (USD Million)
  • Fig. 48 Infectious disease market, 2018 - 2030 (USD Million)
  • Fig. 49 MRSA market, 2018 - 2030 (USD Million)
  • Fig. 50 Clostridium difficile market, 2018 - 2030 (USD Million)
  • Fig. 51 Vancomycin-resistant enterococci market, 2018 - 2030 (USD Million)
  • Fig. 52 Carbapenem-resistant bacteria testing market, 2018 - 2030 (USD Million)
  • Fig. 53 Flu market, 2018 - 2030 (USD Million)
  • Fig. 54 Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
  • Fig. 55 Candida market, 2018 - 2030 (USD Million)
  • Fig. 56 Tuberculosis and drug-resistant TB market, 2018 - 2030 (USD Million)
  • Fig. 57 Meningitis market, 2018 - 2030 (USD Million)
  • Fig. 58 Gastro-intestinal panel testing market, 2018 - 2030 (USD Million)
  • Fig. 59 Chlamydia market, 2018 - 2030 (USD Million)
  • Fig. 60 Gonorrhea market, 2018 - 2030 (USD Million)
  • Fig. 61 HIV market, 2018 - 2030 (USD Million)
  • Fig. 62 Hepatitis C market, 2018 - 2030 (USD Million)
  • Fig. 63 Hepatitis B market, 2018 - 2030 (USD Million)
  • Fig. 64 Other infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 65 Genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 66 Newborn screening market, 2018 - 2030 (USD Million)
  • Fig. 67 Predictive and presymptomatic testing market, 2018 - 2030 (USD Million)
  • Fig. 68 Others market, 2018 - 2030 (USD Million)
  • Fig. 69 Neurological disease market, 2018 - 2030 (USD Million)
  • Fig. 70 Cardiovascular disease market, 2018 - 2030 (USD Million)
  • Fig. 71 Microbiology market, 2018 - 2030 (USD Million)
  • Fig. 72 Others market, 2018 - 2030 (USD Million)
  • Fig. 73 Regional marketplace: key takeaways
  • Fig. 74 Regional outlook, 2023 & 2030
  • Fig. 75 North America molecular diagnostics market: Country movement analysis.
  • Fig. 76 North America molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. key country dynamics
  • Fig. 78 U.S. molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 79 Canada key country dynamics
  • Fig. 80 Canada molecular diagnostics market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-073-6

North America Molecular Diagnostics Market Growth & Trends:

The North America molecular diagnostics market size is expected to reach USD 7.23 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of technologically advanced products is expected to drive the market in North America. Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens. Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.

The rise in the prevalence of chronic & infectious diseases and genetic disorders, such as Alzheimer's disease, Turner syndrome, & Parkinson's disease, is expected to boost the market demand during the forecast period. According to the CDC, chronic diseases such as cancer & diabetes and chronic kidney & respiratory diseases are accountable for 7 in 10 deaths in the U.S. each year. Around 6 out of 10 adults are likely to suffer from a chronic disease in the U.S. In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth. For instance, according to the CDC, in the flu season of 2021-2022, influenza was estimated to affect nine million people.

An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market. Funding plays a significant role in the product development process. For instance, in April 2023, Promega Corporation announced to grant of USD 15,000 in 2023 in academic life sciences research using qPCR. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of Wave platform and novel rapid testing. Such initiatives are expected to encourage SMEs to be involved in the development of novel molecular diagnostic tests.

Key companies are making continuous efforts to launch new products in North America molecular diagnostics and gain a competitive edge by meeting the changing needs of buyers toward more advanced & efficient products. For instance, in November 2022, Cepheid, a Danaher subsidiary, launched Multiplex Vaginal Panel (MVP), a PCR test to detect various conditions, such as trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis.

Furthermore, increasing strategic partnerships among manufacturers and companies for developing novel therapeutics is anticipated to drive market growth. For instance, in February 2023, Thermo Fisher Scientific Inc.partnered with MyLab to procure RT-PCR kits for various infectious diseases, such as tuberculosis & HIV. Moreover, in January 2023, QIAGEN and Helix formed an exclusive alliance to enhance next-generation sequencing companion diagnostics in genetic disorders.

North America Molecular Diagnostics Market Report Highlights:

  • Based on the product, the reagents segment accounted for the largest revenue share of North America molecular diagnostics in 2023 owing to improved efficiency and cost-effectiveness
  • The central laboratories segment dominated the North America molecular diagnostics in 2023 owing to high market penetration and large procedure volumes
  • Based on technology, the PCR segment dominated the North America molecular diagnostics in 2023 and is the most preferred technology amongst doctors and patients for clinical diagnostics
  • The infectious disease segment led the application segment in 2023, attributable to North America's high incidence of infectious diseases
  • The U.S. dominated the regional market due to favorable reimbursement policies, the local presence of leading players, and the presence of well-established healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Test Location segment
      • 1.1.1.3. Technology segment
      • 1.1.1.4. Application segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Test Location Snapshot
  • 2.3. Technology and Application Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in geriatric population
      • 3.2.1.2. Introduction of technologically advanced products
      • 3.2.1.3. Increase in demand for point-of-care testing
      • 3.2.1.4. Growing prevalence of target diseases
      • 3.2.1.5. Increasing external funding for R&D
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of ambiguous regulatory framework
      • 3.2.2.2. High prices of molecular diagnostics tests
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Molecular Diagnostics Market: Product Business Analysis

  • 4.1. North America Molecular Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. North America Molecular Diagnostics Market: Test Location Business Analysis

  • 5.1. North America Molecular Diagnostics Market: Test Location Movement Analysis
  • 5.2. Point-of-Care
    • 5.2.1. Point-of-Care Market, 2018 - 2030 (USD Million)
  • 5.3. Self-test or Over the Counter
    • 5.3.1. Self-test or Over the Counter Market, 2018 - 2030 (USD Million)
  • 5.4. Central Laboratories
    • 5.4.1. Central Laboratories Market, 2018 - 2030 (USD Million)

Chapter 6. North America Molecular Diagnostics Market: Technology Business Analysis

  • 6.1. North America Molecular Diagnostics Market: Technology Movement Analysis
  • 6.2. PCR
    • 6.2.1. PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1. PCR, by Type
      • 6.2.1.1.1. PCR, by Type Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.1. Multiplex PCR
      • 6.2.1.1.1.1.1. Multiplex PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.2. Other PCR
      • 6.2.1.1.1.2.1. Other PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.2. PCR, by Procedure
      • 6.2.1.2.1. PCR, by Procedure Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.1. Nucleic Acid Extraction
      • 6.2.1.2.1.1.1. Nucleic Acid Extraction Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.2. Others
      • 6.2.1.2.1.2.1. Others Market, 2018 - 2030 (USD Million)
      • 6.2.1.3. PCR, by Product
      • 6.2.1.3.1. PCR, by Product Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.1. Instruments
      • 6.2.1.3.1.1.1. Instruments Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.2. Reagents
      • 6.2.1.3.1.2.1. Reagents Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.3. Others
      • 6.2.1.3.1.3.1. Others Market, 2018 - 2030 (USD Million)
  • 6.3. In Situ Hybridization (ISH)
    • 6.3.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Million)
    • 6.3.2. Instruments
      • 6.3.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.3.3. Reagents
      • 6.3.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.3.4. Others Market, 2018 - 2030 (USD Million)
      • 6.3.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 6.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Instruments
      • 6.4.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.4.3. Reagents
      • 6.4.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.4.4. Others Market, 2018 - 2030 (USD Million)
      • 6.4.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Chips and Microarrays
    • 6.5.1. Chips and Microarrays Market, 2018 - 2030 (USD Million)
    • 6.5.2. Instruments
      • 6.5.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.5.3. Reagents
      • 6.5.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.5.4. Others Market, 2018 - 2030 (USD Million)
      • 6.5.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.6. Mass Spectroscopy
    • 6.6.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
    • 6.6.2. Instruments
      • 6.6.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.6.3. Reagents
      • 6.6.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.6.4. Others Market, 2018 - 2030 (USD Million)
      • 6.6.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. Sequencing Market, 2018 - 2030 (USD Million)
    • 6.7.2. Instruments
      • 6.7.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.7.3. Reagents
      • 6.7.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.7.4. Others Market, 2018 - 2030 (USD Million)
      • 6.7.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.8. Transcription Mediated Amplification (TMA)
    • 6.8.1. Transcription Mediated Amplification (TMA) Market, 2018 - 2030 (USD Million)
    • 6.8.2. Instruments
      • 6.8.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.8.3. Reagents
      • 6.8.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.8.4. Others Market, 2018 - 2030 (USD Million)
      • 6.8.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2018 - 2030 (USD Million)
    • 6.9.2. Instruments
      • 6.9.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.9.3. Reagents
      • 6.9.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.9.4. Others Market, 2018 - 2030 (USD Million)
      • 6.9.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. North America Molecular Diagnostics Market: Application Business Analysis

  • 7.1. North America Molecular Diagnostics Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Million)
    • 7.2.2. Breast Cancer
      • 7.2.2.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.3. Prostate Cancer
      • 7.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.4. Colorectal Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.4.1. Colorectal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.5. Cervical Cancer
      • 7.2.5.1. Cervical Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.6. Kidney Cancer
      • 7.2.6.1. Kidney Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.7. Liver Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.7.1. Liver Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.8. Blood Cancer
      • 7.2.8.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.9. Lung Cancer
      • 7.2.9.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.10. Other Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.10.1. Other Cancer Market, 2018 - 2030 (USD Million)
  • 7.3. Pharmacogenomics
    • 7.3.1. Pharmacogenomics Market, 2018 - 2030 (USD Million)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 7.4.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
      • 7.4.2.1. Methicillin-resistant Staphylococcus Aureus (MRSA) Market, 2018 - 2030 (USD Million)
    • 7.4.3. Clostridium Difficile
      • 7.4.3.1. Clostridium Difficile Market, 2018 - 2030 (USD Million)
    • 7.4.4. Vancomycin-resistant Enterococci (VRE)
      • 7.4.4.1. Vancomycin-resistant Enterococci (VRE) Market, 2018 - 2030 (USD Million) Instruments
    • 7.4.5. Carbapenem-resistant Bacteria
      • 7.4.5.1. Carbapenem-resistant Bacteria Market, 2018 - 2030 (USD Million)
    • 7.4.6. Flu
      • 7.4.6.1. Flu Market, 2018 - 2030 (USD Million)
    • 7.4.7. Candida Market, 2018 - 2030 (USD Million)
      • 7.4.7.1. Candida Market, 2018 - 2030 (USD Million)
    • 7.4.8. Tuberculosis and Drug-resistant TBA
      • 7.4.8.1. Tuberculosis and Drug-resistant TBA Market, 2018 - 2030 (USD Million)
    • 7.4.9. Meningitis
      • 7.4.9.1. Meningitis Market, 2018 - 2030 (USD Million)
    • 7.4.10. Gastrointestinal Panel Testing
      • 7.4.10.1. Gastrointestinal Panel Testing Market, 2018 - 2030 (USD Million)
    • 7.4.11. Chlamydia
      • 7.4.11.1. Chlamydia Market, 2018 - 2030 (USD Million)
    • 7.4.12. Gonorrhea
      • 7.4.12.1. Gonorrhea Market, 2018 - 2030 (USD Million)
    • 7.4.13. HIV
      • 7.4.13.1. HIV Market, 2018 - 2030 (USD Million)
    • 7.4.14. Hepatitis C
      • 7.4.14.1. Hepatitis C Market, 2018 - 2030 (USD Million)
    • 7.4.15. Hepatitis B
      • 7.4.15.1. Hepatitis B Market, 2018 - 2030 (USD Million)
    • 7.4.16. Others Infectious Diseases
      • 7.4.16.1. Other Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 7.5. Genetic Testing
    • 7.5.1. Genetic Testing Market, 2018 - 2030 (USD Million)
    • 7.5.2. Newborn Screening
      • 7.5.2.1. Newborn Screening Market, 2018 - 2030 (USD Million)
    • 7.5.3. Predictive and Presymptomatic Testing
      • 7.5.3.1. Predictive and Presymptomatic Market, 2018 - 2030 (USD Million)
    • 7.5.4. Other Genetic Testing Market, 2018 - 2030 (USD Million) Instruments
      • 7.5.4.1. Other Genetic Testing Market, 2018 - 2030 (USD Million)
  • 7.6. Neurological Disease
    • 7.6.1. Neurological Disease Market, 2018 - 2030 (USD Million)
  • 7.7. Cardiovascular Disease
    • 7.7.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
  • 7.8. Microbiology
    • 7.8.1. Microbiology Market, 2018 - 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. North America Molecular Diagnostics Market: Country Business Analysis

  • 8.1. North America
    • 8.1.1. North America Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.2. U.S.
      • 8.1.2.1. Key Country Dynamics
      • 8.1.2.2. Target Disease Prevalence
      • 8.1.2.3. Competitive Scenario
      • 8.1.2.4. Regulatory Framework
      • 8.1.2.5. U.S. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.3. Canada
      • 8.1.3.1. Key Country Dynamics
      • 8.1.3.2. Target Disease Prevalence
      • 8.1.3.3. Competitive Scenario
      • 8.1.3.4. Regulatory Framework
      • 8.1.3.5. Canada Molecular Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 9. North America Molecular Diagnostics Market: Competitive Landscape

  • 8.1. Participant Categorization
    • 9.1.1. BD
      • 9.1.1.1. Overview
      • 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.1.3. Product Benchmarking
      • 9.1.1.4. Strategic Initiatives
    • 9.1.2. Bio-Rad Laboratories, Inc.
      • 9.1.2.1. Overview
      • 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.2.3. Product Benchmarking
      • 9.1.2.4. Strategic Initiatives
    • 9.1.3. Abbott
      • 9.1.3.1. Overview
      • 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.3.3. Product Benchmarking
      • 9.1.3.4. Strategic Initiatives
    • 9.1.4. Agilent Technologies, Inc.
      • 9.1.4.1. Overview
      • 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.4.3. Product Benchmarking
      • 9.1.4.4. Strategic Initiatives
    • 9.1.5. Danaher
      • 9.1.5.1. Overview
      • 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.5.3. Product Benchmarking
      • 9.1.5.4. Strategic Initiatives
    • 9.1.6. Hologic Inc. (Gen Probe)
      • 9.1.6.1. Overview
      • 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.6.3. Product Benchmarking
      • 9.1.6.4. Strategic Initiatives
    • 9.1.7. Illumina, Inc.
      • 9.1.7.1. Overview
      • 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.7.3. Product Benchmarking
      • 9.1.7.4. Strategic Initiatives
    • 9.1.8. Johnson & Johnson Services, Inc.
      • 9.1.8.1. Overview
      • 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.8.3. Product Benchmarking
      • 9.1.8.4. Strategic Initiatives
    • 9.1.9. Thermo Fisher Scientific Inc.
      • 9.1.9.1. Overview
      • 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.9.3. Product Benchmarking
      • 9.1.9.4. Strategic Initiatives
    • 9.1.10. F. Hoffmann-La Roche, Ltd.
      • 9.1.10.1. Overview
      • 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.10.3. Product Benchmarking
      • 9.1.10.4. Strategic Initiatives
  • 9.2. Participant's Overview
  • 9.3. Financial Performance
  • 9.4. Product Benchmarking
  • 9.5. Company Market Share Analysis, 2023
  • 9.6. Strategy Mapping
    • 9.6.1. Expansion
    • 9.6.2. Acquisition
    • 9.6.3. Product/Service Launch
    • 9.6.4. Others

Chapter 10. Analyst View